New combo therapy aims to tackle tough sarcomas
NCT ID NCT07342322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a new treatment for soft tissue sarcoma that combines a special type of radiation with immunotherapy and immune-boosting drugs. The goal is to see if this combination can shrink tumors and improve outcomes for people with advanced or recurrent sarcoma. The study plans to enroll 25 participants and is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with spatially fractionated radiotherapy and immune-boosting drugs (GM-CSF and thymalfasin)
What this could lead to
If successful, this could offer a new treatment option for people with advanced soft tissue sarcoma that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 25 people, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••